Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faecal microbiota transplantation
- Development stage
- Preclinical
- Lead developer
- Aarhus University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Faecal microbiota transplantation (FMT) is an investigational live biotherapeutic product involving the transfer of fecal microorganisms from a healthy donor to a recipient. [5, 9] The aim is to restore a healthy gut microbiome, which is often disturbed (dysbiosis) in various diseases. [5, 7] This specific intervention, studied by Aarhus University, targets patients with liver cirrhosis to prevent complications, slow disease progression, and reduce mortality. [3, 9] The underlying principle is that correcting dysbiosis will improve gut barrier function, reduce systemic inflammation, and modulate the gut-liver axis. [2, 4, 5]
- Other names
- FMTfaecal microbial transplantfecal microbiota transplantation
Beyond the preview
Go deeper on faecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faecal microbiota transplantation.